search
Back to results

Vulvovaginal Candidiasis in Canadian Females (THRIVE-yeast)

Primary Purpose

Candidiasis, Vulvovaginal

Status
Recruiting
Phase
Early Phase 1
Locations
Canada
Study Type
Interventional
Intervention
Fluconazole 150 mg
Boric Acid Supp,Vag
Sponsored by
University of Manitoba
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Candidiasis, Vulvovaginal

Eligibility Criteria

18 Years - 50 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Female
  • Between ages of 18 and 50 years.

Exclusion Criteria:

  • Currently pregnant
  • Trying to get pregnant
  • Have had a hysterectomy

Sites / Locations

  • Health Science Centre (HSC)Recruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

No Intervention

No Intervention

Arm Label

Recurrent Infection Cohort - symptomatic

Assumed First-Time Infection Cohort

Asymptomatic Cohort

Recurrent Infection Cohort - asymptomatic

Arm Description

Participants with a history of recurrent vulvovaginal candidiasis infections who have an active symptomatic infection when they come to clinic

Participants with their suspected first vulvovaginal candidiasis infection

Participants with no history of vulvovaginal candidiasis

Participants with a history of recurrent vulvovaginal candidiasis infections who do not have an active symptomatic infection when they come to clinic

Outcomes

Primary Outcome Measures

Fungal Diversity
Use culture-based methods, flow cytometry, and genome sequencing to: Test how genotypic diversity, genetic relatedness, and drug resistance and tolerance changes in the fungal population from the assumed first-time infection cohort and recurrent infection cohort participants before and after treatment with either fluconazole or boric acid. How the vaginal fungal population diversity differs between symptomatic and asymptomatic participants. Test how the vaginal fungal isolates in participants with VVC are related to rectal, oral, and skin fungal isolates.

Secondary Outcome Measures

Bacterial Diversity
Using 16S-rRNA sequencing and meta-proteomic to characterize the bacterial diversity changes pre-and post- drug treatment for VVC.
Host Functional Changes
Host proteome of the vaginal samples will be assessed using proteomics to determine any underlying inflammatory or barrier pathways that associate with treatment of VVC.

Full Information

First Posted
June 10, 2021
Last Updated
January 31, 2023
Sponsor
University of Manitoba
Collaborators
Manitoba Medical Service Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT04930107
Brief Title
Vulvovaginal Candidiasis in Canadian Females
Acronym
THRIVE-yeast
Official Title
Prospective Studies of Vaginal Yeast and Microbiome Related to Vulvovaginal Candidiasis in Canadian Females
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 7, 2021 (Actual)
Primary Completion Date
April 30, 2024 (Anticipated)
Study Completion Date
April 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Manitoba
Collaborators
Manitoba Medical Service Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes

5. Study Description

Brief Summary
Vulvovaginal candidiasis (VVC; colloquially referred to as a 'yeast infection') is a prevalent mucosal infection caused by Candida spp. that affects ~75% of women at least once in their life. VVC usually responds well to treatment, yet a small but significant fraction of women experience recurrent yeast infections even with weekly treatment. A further complication in understanding the causes of recurrent infections is that approximately one in five females have vaginal yeast present without any symptoms at any given point. The link between fungi, other microbes in the vagina ("microbiome"), and the human immune system remain poorly understood in the switch from having yeast present in the vagina without any symptoms and symptomatic yeast infections. Fungi also compose a normal component of the microbiome at other sites in the body (e.g., oral, skin, gastrointestinal tract, rectum) where they may serve as a source of re-infection following treatment. In addition to the commonly prescribed 'first choice' antifungal drug fluconazole, a second-line treatment, boric acid, has shown promise in the literature and has been used locally with success at increasing the time between recurrent infections. A drawback of this therapy, however, is cost, as it is a compounded medication, and patients have to pay out of pocket. The purpose of this study is to understand how the yeast and bacterial microbial communities differ for females with recurrent infections from females with their first yeast infection and females with vaginal yeast present without any symptoms, and to track yeast diversity following treatment with either boric acid or fluconazole. The investigators hypothesize that they will identify multiple subpopulations of yeast at multiple anatomical body sites in females with VVC and recurrent VVC. They anticipate finding evidence for recurrent infection from secondary sites by linking genomic diversity of vaginal yeast strains during symptomatic infection to strains from other body sites. They hypothesize that yeast isolated from females with recurrent infections will exhibit different drug response phenotypes than yeast from females with asymptomatic vaginal yeast. They hypothesize that the vaginal microbiome of post-treatment patients treated with boric acid will differ from that of fluconazole. Combined, they hypothesize that post-treatment response will differ between the drugs, indicating that treatment specifics influence the vaginal environment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Candidiasis, Vulvovaginal

7. Study Design

Primary Purpose
Basic Science
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
105 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Recurrent Infection Cohort - symptomatic
Arm Type
Active Comparator
Arm Description
Participants with a history of recurrent vulvovaginal candidiasis infections who have an active symptomatic infection when they come to clinic
Arm Title
Assumed First-Time Infection Cohort
Arm Type
Active Comparator
Arm Description
Participants with their suspected first vulvovaginal candidiasis infection
Arm Title
Asymptomatic Cohort
Arm Type
No Intervention
Arm Description
Participants with no history of vulvovaginal candidiasis
Arm Title
Recurrent Infection Cohort - asymptomatic
Arm Type
No Intervention
Arm Description
Participants with a history of recurrent vulvovaginal candidiasis infections who do not have an active symptomatic infection when they come to clinic
Intervention Type
Drug
Intervention Name(s)
Fluconazole 150 mg
Intervention Description
Treatment will be offered to participants if clinical exam and clinical samples are consistent with vulvovaginal candidiasis (VVC). Females presenting with a suspected first-time yeast infection will be treated with fluconazole 150 mg orally.
Intervention Type
Drug
Intervention Name(s)
Boric Acid Supp,Vag
Intervention Description
Treatment will be offered to participants if clinical exam and clinical samples are consistent with vulvovaginal candidiasis (VVC). Women that have had a prior documented VVC infection that has recurred on fluconazole will be treated with boric acid, 600 mg intravaginally at bedtime for 7 days.
Primary Outcome Measure Information:
Title
Fungal Diversity
Description
Use culture-based methods, flow cytometry, and genome sequencing to: Test how genotypic diversity, genetic relatedness, and drug resistance and tolerance changes in the fungal population from the assumed first-time infection cohort and recurrent infection cohort participants before and after treatment with either fluconazole or boric acid. How the vaginal fungal population diversity differs between symptomatic and asymptomatic participants. Test how the vaginal fungal isolates in participants with VVC are related to rectal, oral, and skin fungal isolates.
Time Frame
One month
Secondary Outcome Measure Information:
Title
Bacterial Diversity
Description
Using 16S-rRNA sequencing and meta-proteomic to characterize the bacterial diversity changes pre-and post- drug treatment for VVC.
Time Frame
One month
Title
Host Functional Changes
Description
Host proteome of the vaginal samples will be assessed using proteomics to determine any underlying inflammatory or barrier pathways that associate with treatment of VVC.
Time Frame
One month

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Female Between ages of 18 and 50 years. Exclusion Criteria: Currently pregnant Trying to get pregnant Have had a hysterectomy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Vanessa Poliquin, MD
Phone
204-787-4796
Email
vpoliquin@hsc.mb.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Vanessa HSC Women's Health Research Program, MD
Phone
204-975-7723
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Aleeza Gerstein, PhD
Organizational Affiliation
University of Manitoba
Official's Role
Principal Investigator
Facility Information:
Facility Name
Health Science Centre (HSC)
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R3A 1R9
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
Phone
204-975-7723

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified proteomics and microbiome data collected will be placed into a freely available data repository after peer review of publications via Genbank. The proteomic expression data shall be made available by depositing the raw, untransformed and normalized counts on our servers. Whole genome sequencing data will be made available on the National Center for Biotechnology Information (NCBI) short reads archive. Any other functional data shall be made available with the journal publications in the text, or as supplementary material at the publisher's online website, or in data repositories (e.g., Dryad, https://datadryad.org).
IPD Sharing Time Frame
Following publication in peer-reviewed journal articles, data available indefinitely.
IPD Sharing Access Criteria
Following publication, external collaborators wishing to make use of THRIVE-yeast data must first contact the PI and submit a written proposal to request access to de-identified data. The PI will consult with University of Manitoba Office of Research Services to create a Data Sharing Transfer Agreement.

Learn more about this trial

Vulvovaginal Candidiasis in Canadian Females

We'll reach out to this number within 24 hrs